By Josh White
Date: Friday 25 Nov 2022
LONDON (ShareCast) - (Sharecast News) - Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.
"Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m," the board said in its short statement.
At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 3.20p |
Change Today | -0.050p |
% Change | -1.54 % |
52 Week High | 4.35 |
52 Week Low | 2.54 |
Volume | 879,682 |
Shares Issued | 237.95m |
Market Cap | £7.61m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:13 | 80,000 @ 3.35p |
15:07 | 147 @ 3.40p |
13:13 | 49,832 @ 3.12p |
13:09 | 20,234 @ 3.12p |
12:19 | 13,301 @ 3.12p |
You are here: research